Actual questions of medicine therapy of hormonoresistant and metastatic prostate cancer

Abstract

Prostate cancer (PC) is a heterogeneous disease with several different stages necessitating a broad range of therapies to treat patients diagnosed at different points in the disease course. Androgen deprivation therapy (ADT) is commonly used to treat aii stages of prostate cancer but is associated with toxicities that limit its use, particularly in patients with asymptomatic disease or existing comorbidities for whom such toxicity is not justified. ADT resource at patients with PC is limited and makes about 18-24 months then illness progresses and accepts generalised and/or hormone-resistant form. In this connection the factor develops various regimens ADT such as - an intermittent hormone therapy (IHT) which is investigated as alternative continuous HT. Study of 2 phases have shown efficiency IHT, improvement of quality of a life. It is noted that IHT has no negative effect for the period of development of advance and/or on survival rate. Despite advantage of a docetaxel in treatment of patients of generalised form PC, survival rate medians makes about 2,4 months, and treatment carrying out is interfaced to high toxicity. Low efficiency of existing drugs - also is a vital issue limiting efficiency of treatment of patients with hormone-resistant and metastatic forms of PC.

Keywords

prostate cancer (PC) / generalised PC form / androgen deprivation and intermittent hormone therapy

RIGHTS & PERMISSIONS

Kaprin A.D., Gafanov R.A., Shaipov M.K., Shestakov A.V., Meskich A.V.